T cells play a big role in bringing cell and gene therapies to patients. Despite this clinical potential, scientists developing T cell therapies such as chimeric antigen receptor (CAR)-T cells, ...
In January 2024, the FDA updated its guidance on CAR-T therapies, emphasizing the need for enhanced safety and quality measures. This update followed a series of warnings regarding the risk of T cell ...
Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.
The most common method for evaluating replication competency of lentivirus and AAV vectors is through serial passaging of virus in cell culture lines and subsequent identification of viral particles ...
Images of human cells at different stages of mitosis. Chromosomes are colored cyan, spindle microtubules in red and spindle poles are yellow. Each day, hundreds of billions of cells in our body cycle ...
Like traditional biologics, cell and gene therapies (CGTs) must meet safety and efficacy standards before they can be administered to human patients. But the manufacturing processes used for this new ...
When it comes to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and certain forms of dementia, ...
Since the FDA first approved CAR-T cell therapy in 2017, eight CAR-T drugs have emerged, six of which have been fully approved by the FDA. This groundbreaking cell therapy has brought about a series ...
Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.
When it comes to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and certain forms of dementia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback